Halozyme Therapeutics reported $189.37M in Trade Debtors for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Trade Debtors Change
DBV Technologies DBVT:US 8.21M 3.7M
Acadia Pharmaceuticals ACAD:US $ 68.89M 5.41M
Agios Pharmaceuticals AGIO:US $ 4.3M 1.6M
Alnylam Pharmaceuticals ALNY:US $ 142.27M 14.26M
Amarin AMRN:US $ 143.94M 33.71M
Amgen AMGN:US $ 5327M 250M
Baxter International BAX:US $ 2473M 2M
Cara Therapeutics CARA:US $ 9.17M 5.54M
Cytokinetics CYTK:US $ 1.97M 4.08M
Eli Lilly And LLY:US $ 7672.4M 133.3M
Esperion Therapeutics ESPR:US 27.84M 2.73M
Halozyme Therapeutics HALO:US $ 189.37M 75.61M
Intercept Pharmaceuticals ICPT:US $ 27.52M 18.63M
Intra Cellular Therapies ITCI:US $ 46.98M 14.14M
Intrexon XON:US $ 0.56M 24.3M
JAZZ PHA JAZZ:US $ 594.03M 21.64M
Mannkind MNKD:US $ 15.03M 5.21M
Nektar Therapeutics NKTR:US $ 10.01M 20.21M
Peregrine Pharmaceuticals PPHM:US $ 25.92M 5.44M
Rigel Pharmaceuticals RIGL:US $ 17.2M 1.96M
United Therapeutics UTHR:US $ 173.4M 2.9M
Vanda Pharmaceuticals VNDA:US $ 28.8M 1.69M